An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.

The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.

Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound.

Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound.